Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 05/31/2025 | 02/28/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 19.16% | 28.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 19.16% | 28.11% | |||
| Cost of Revenue | 15.83% | 42.75% | |||
| Gross Profit | 22.68% | 15.57% | |||
| SG&A Expenses | -49.34% | 25.53% | |||
| Depreciation & Amortization | 128.30% | 19.14% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -34.90% | 27.37% | |||
| Operating Income | 61.81% | -27.01% | |||
| Income Before Tax | 56.20% | -18.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 56.20% | -18.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 56.20% | -18.48% | |||
| EBIT | 61.81% | -27.01% | |||
| EBITDA | 64.10% | -29.75% | |||
| EPS Basic | 58.06% | -16.25% | |||
| Normalized Basic EPS | 58.62% | -16.00% | |||
| EPS Diluted | 58.06% | -16.25% | |||
| Normalized Diluted EPS | 58.62% | -16.00% | |||
| Average Basic Shares Outstanding | 4.47% | 1.27% | |||
| Average Diluted Shares Outstanding | 4.47% | 1.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||